TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer

November 7, 2022

https://www.globenewswire.com/news-release/2022/11/07/2549673/0/en/TCR-Therapeutics-Presents-Preclinical-Data-on-Functional-Activity-of-Gavo-cel-at-the-Society-for-Immunotherapy-of-Cancer.html

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the poster presentation of new preclinical data at the Society for Immunotherapy of Cancer (SITC) Conference 37th Annual Meeting, taking place November 8-12, 2022. The poster entitled “The Functional Activity of gavo-cel TRuC-T Cells is Not Impaired by Soluble Mesothelin” highlights preclinical data evaluating the impact of soluble mesothelin at high, supraphysiological levels on the functional activity of the Company’s proprietary autologous and allogeneic mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells.

Read more at globenewswire.com

Related news for (TCRR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.